pain might be attributed to the fact that the primary disease in our study was advanced pancreatic cancer, and many patients were being administered non-steroidal antiinflammatory drugs (NSAIDs) for cancer-related pain relief. Given that NSAIDs are effective in relieving both bone pain and cancer-related pain, it is likely that the administration of NSAIDs might have ameliorated bone pain.
Finally, Dr. Chen et al. argue that it is too early to determine the cost-effectiveness of mFOLFIRINOX combined with Peg G. We agree with this opinion and feel that largescale, multi-center prospective trials will be required in order to determine the cost-effectiveness. Such future studies will be useful for assessing not only the cost-effectiveness but also the non-hematological toxicities of mFOLFIRINOX combined with Peg G.
